Paracyclophanes: A novel class of water-soluble inhibitors of HIV proteinase

Journal of Medicinal Chemistry

Volumn 39, Issue 17, 1996, Pages 3291-3299

  Ettmayer, Peter ^a   Billich, Andreas ^a   Hecht, Peter ^a   Rosenwirth, Brigitte ^a   Gstach, Hubert ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PARACYCLOPHANE DERIVATIVE; PROTEINASE INHIBITOR; SAQUINAVIR; SDZ PRI 053; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANIMALS; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; ETHERS, CYCLIC; FEMALE; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; PEPTIDES, CYCLIC; RECOMBINANT PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029785735     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950641i     Document Type: Article

References (31)

1. Scholz, D.; Billich, A.; Charpiot, B.; Ettmayer, P.; Lehr, P.; Rosenwirth, B.; Schreiner, E.; Gstach, H. Inhibitors of HIV-1 Proteinase Containing 2-Heterosubstituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid: Synthesis, Enzyme Inhibition, and Antiviral Activity, J. Med. Chem. 1994, 37, 3079-3089.
2. The nomenclature used for describing the individual amino acid residues (P3, P2, P1, P1′, P2′, etc.) of a substrate and the corresponding subsites (S3, S2, S1, S1′, S2′, etc.) of a protease is that of Schechter and Berger: Schechter, I.; Berger, A. On the Size of the Active Site in Proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967, 27, 157-162.
3. Billich, A.; Charpiot, B.; Fricker, G.; Gstach, H.; Lehr, P.; Peichl, P.; Scholz, D.; Rosenwirth, B. HIV Proteinase Inhibitors Containing 2-Aminobenzylstatine as a Novel Scissile Bond Replacement: Biochemical and Pharmacological Characterization. Antivir. Res. 1994, 25, 215-233.
4. (a) Billich, A.; Fricker, G.; Müller, I.; Donatsch, P.; Ettmayer, P.; Gstach H.; Lehr P.; Peichl P.; Scholz D.; Rosenwirth B. SDZ PRI 053, an Orally Bioavailable Human Immunodeficiency Virus Type 1 Proteinase Inhibitor Containing the 2-Aminobenzylstatine Moiety. Antimicrob. Agents Chemother. 1995, 39, 1406-1413.
5. (b) Lehr, P.; Billich, A.; Charpiot, B.; Gstach, H.; Ettmayer, P.; Scholz, D.; Rosenwirth, B. Inhibitors of HIV-I Protease Containing 2-Aminobenzyl Substituted 4-Amino-3-hydroxy-5-phenylpentanoic Acid (AHPPA): Synthesis, Activity, and Oral Bioavailability. J. Med. Chem. 1996, 39, 2060-2067.
6. Billich, A.; Scholz, D.; Charpiot, B.; Gstach, H.; Lehr P.; Peichl, P.; Rosenwirth B. Potent and Orally Bioavailable HIV-I Proteinase Inhibitors Containing the 2-Aminobenzylstatine Moiety. Antivir. Chem. Chemother. 1995, 6(5), 327-336.
7. Kempf, D. J.; Codacovi, L.; Wang, X. C.; Kohlbrenner, W. E.; Wideburg, N. E.; Saldivar, A.; Vasavanonda, S.; Marsh, K. C.; Bryant, P.; Sham, H. L. Symmetry-based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol. J. Med. Chem. 1993, 36, 320-330.
8. Kageyama, S.; Anderson, B. D.; Hoesterey, B. L.; Hayashi, H.; Kiso, Y.; Flora, K. P.; Mitsuya, H. Protein Binding of Human Immunodeficiency Virus Protease Inhibitor KNI-272 and Alteration of its in Vitro Antiretroviral Activity in the Presence of High Concentrations of Proteins. Antimicrob. Agents Chemother. 1994, 38, 1107-1111.
9. Toniolo, C.; Bianco, A.; Maggini, M.; Scorrano, G.; Prato, M.; Marastoni, M.; Tomatis, R.; Spisani, S.; Palu, G.; Blair, E. D. A Bioactive Fullerene Peptide. J. Med. Chem. 1994, 37, 4558-4562. Brinekworth, R.; Woon, T.; Fairlie, D. Inhibition of HIV-1 Proteinase by non-Peptide Carboxylates. Biochem Biophys. Res. Commun. 1991, 176, 241-246. DesJarlais, R.; Seibel, G.; Kuntz, I.; Furth, P.; Alvarez, J.; Ortiz de Montellano, P.; DeCamp, D.; Babe, L.; Craik, C.; Structure Based Design of Nonpeptide Inhibitors Specific for the Human Immunodeficieny Virus 1 Protease. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6644-6648.
10. Toniolo, C.; Bianco, A.; Maggini, M.; Scorrano, G.; Prato, M.; Marastoni, M.; Tomatis, R.; Spisani, S.; Palu, G.; Blair, E. D. A Bioactive Fullerene Peptide. J. Med. Chem. 1994, 37, 4558-4562. Brinekworth, R.; Woon, T.; Fairlie, D. Inhibition of HIV-1 Proteinase by non-Peptide Carboxylates. Biochem Biophys. Res. Commun. 1991, 176, 241-246. DesJarlais, R.; Seibel, G.; Kuntz, I.; Furth, P.; Alvarez, J.; Ortiz de Montellano, P.; DeCamp, D.; Babe, L.; Craik, C.; Structure Based Design of Nonpeptide Inhibitors Specific for the Human Immunodeficieny Virus 1 Protease. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6644-6648.
11. Toniolo, C.; Bianco, A.; Maggini, M.; Scorrano, G.; Prato, M.; Marastoni, M.; Tomatis, R.; Spisani, S.; Palu, G.; Blair, E. D. A Bioactive Fullerene Peptide. J. Med. Chem. 1994, 37, 4558-4562. Brinekworth, R.; Woon, T.; Fairlie, D. Inhibition of HIV-1 Proteinase by non-Peptide Carboxylates. Biochem Biophys. Res. Commun. 1991, 176, 241-246. DesJarlais, R.; Seibel, G.; Kuntz, I.; Furth, P.; Alvarez, J.; Ortiz de Montellano, P.; DeCamp, D.; Babe, L.; Craik, C.; Structure Based Design of Nonpeptide Inhibitors Specific for the Human Immunodeficieny Virus 1 Protease. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6644-6648.
12. Weber, A. E.; Steiner, M. G.; Krieter, P. A.; Colletti, A. E.; Tata, J. R.; Halgren, T. A.; Ball, R. G.; Doyle, J. J.; Schorn, T. W.; Stearns, R. A. Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1992, 35, 3755-73. Reily, M. D.; Thanabal, V.; Lunney, E. A.; Repine, J. T.; Humblet, C. C.; Wagner, G. Design, Synthesis and Solution Structure of a Renin Inhibitor. Structural Constraints from NOE, and Homonuclear and Heteronuclear Coupling Constants Combined with Distance Geometry Calculations. FEBS Lett. 1992, 302, 97-103. Weber, A. E.; Halgren, T. A.; Doyle, J. J.; Lynch, R. J.; Siegl, P. K.; Parsons, W. H; Greenlee, W. J.; Patchett, A. A. Design and Synthesis of P2-P1′-linked Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1991, 34, 2692-2701. Fesik, S. W.; Bolis, G.; Sham, H. L.; Olejniczak, E. T. Structure Refinement of a Cyclic Peptide from Two-Dimensional NMR Data and Molecular Modeling. Biochemistry 1987, 26, 1851-1859.
13. Weber, A. E.; Steiner, M. G.; Krieter, P. A.; Colletti, A. E.; Tata, J. R.; Halgren, T. A.; Ball, R. G.; Doyle, J. J.; Schorn, T. W.; Stearns, R. A. Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1992, 35, 3755-73. Reily, M. D.; Thanabal, V.; Lunney, E. A.; Repine, J. T.; Humblet, C. C.; Wagner, G. Design, Synthesis and Solution Structure of a Renin Inhibitor. Structural Constraints from NOE, and Homonuclear and Heteronuclear Coupling Constants Combined with Distance Geometry Calculations. FEBS Lett. 1992, 302, 97-103. Weber, A. E.; Halgren, T. A.; Doyle, J. J.; Lynch, R. J.; Siegl, P. K.; Parsons, W. H; Greenlee, W. J.; Patchett, A. A. Design and Synthesis of P2-P1′-linked Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1991, 34, 2692-2701. Fesik, S. W.; Bolis, G.; Sham, H. L.; Olejniczak, E. T. Structure Refinement of a Cyclic Peptide from Two-Dimensional NMR Data and Molecular Modeling. Biochemistry 1987, 26, 1851-1859.
14. Weber, A. E.; Steiner, M. G.; Krieter, P. A.; Colletti, A. E.; Tata, J. R.; Halgren, T. A.; Ball, R. G.; Doyle, J. J.; Schorn, T. W.; Stearns, R. A. Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1992, 35, 3755-73. Reily, M. D.; Thanabal, V.; Lunney, E. A.; Repine, J. T.; Humblet, C. C.; Wagner, G. Design, Synthesis and Solution Structure of a Renin Inhibitor. Structural Constraints from NOE, and Homonuclear and Heteronuclear Coupling Constants Combined with Distance Geometry Calculations. FEBS Lett. 1992, 302, 97-103. Weber, A. E.; Halgren, T. A.; Doyle, J. J.; Lynch, R. J.; Siegl, P. K.; Parsons, W. H; Greenlee, W. J.; Patchett, A. A. Design and Synthesis of P2-P1′-linked Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1991, 34, 2692-2701. Fesik, S. W.; Bolis, G.; Sham, H. L.; Olejniczak, E. T. Structure Refinement of a Cyclic Peptide from Two-Dimensional NMR Data and Molecular Modeling. Biochemistry 1987, 26, 1851-1859.
15. Weber, A. E.; Steiner, M. G.; Krieter, P. A.; Colletti, A. E.; Tata, J. R.; Halgren, T. A.; Ball, R. G.; Doyle, J. J.; Schorn, T. W.; Stearns, R. A. Highly Potent, Orally Active Diester Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1992, 35, 3755-73. Reily, M. D.; Thanabal, V.; Lunney, E. A.; Repine, J. T.; Humblet, C. C.; Wagner, G. Design, Synthesis and Solution Structure of a Renin Inhibitor. Structural Constraints from NOE, and Homonuclear and Heteronuclear Coupling Constants Combined with Distance Geometry Calculations. FEBS Lett. 1992, 302, 97-103. Weber, A. E.; Halgren, T. A.; Doyle, J. J.; Lynch, R. J.; Siegl, P. K.; Parsons, W. H; Greenlee, W. J.; Patchett, A. A. Design and Synthesis of P2-P1′-linked Macrocyclic Human Renin Inhibitors. J. Med. Chem. 1991, 34, 2692-2701. Fesik, S. W.; Bolis, G.; Sham, H. L.; Olejniczak, E. T. Structure Refinement of a Cyclic Peptide from Two-Dimensional NMR Data and Molecular Modeling. Biochemistry 1987, 26, 1851-1859.
16. Podlogar, B. L.; Fair, R. A.; Friedrich, D.; Tarnus, C.; Huber E. W.; Cregge, R. J.; Schiriin, D. Design, Synthesis, and Conformational Analysis of a Novel Macrocyclic HIV-Protease Inhibitor. J. Med. Chem. 1994, 37, 3684-3692. Smith, R. A.; Coles, P. J.; Chen, J. J.; Robinson, V. J.; Macdonald, I. D.; Carriere, J.; Krantz, A. Design, Synthesis, and Activity of Conformationally-Constrained Macrocyclic Peptide-Based Inhibitors of HIV Protease. Bioorg. Med. Chem. Lett. 1994, 4, 2217-2222.
17. Podlogar, B. L.; Fair, R. A.; Friedrich, D.; Tarnus, C.; Huber E. W.; Cregge, R. J.; Schiriin, D. Design, Synthesis, and Conformational Analysis of a Novel Macrocyclic HIV-Protease Inhibitor. J. Med. Chem. 1994, 37, 3684-3692. Smith, R. A.; Coles, P. J.; Chen, J. J.; Robinson, V. J.; Macdonald, I. D.; Carriere, J.; Krantz, A. Design, Synthesis, and Activity of Conformationally-Constrained Macrocyclic Peptide-Based Inhibitors of HIV Protease. Bioorg. Med. Chem. Lett. 1994, 4, 2217-2222.
18. For full details of the docking experiments see: Krömer, R. T.; Ettmayer, P.; Hecht, P. 3D Qantitative Structure-Activity Relationships of Human Immunodeficiency Virus Type-1 Proteinase Inhibitors: Comparative Molecular Field Analysis of 2 Heterosubstituted Staline Derivatives - Implications for the Design of Novel Inhibitors. J. Med. Chem. 1995, 38, 4917-4928.
19. The structures were minimized in a two-step procedure: (A) using the standard Tripos Force Field without electrostatics applying the Powell minimization technique. The convergence criteria were set to be an energy change of <0.05 kcal/mol in two consecutive steps; (B) the resulting structure was minimized under the same conditions in the protease environment (brook-haven: 4HVP without inhibitor) which was defined as completely rigid. Distance constraints corresponding to a set of hydrogen bonds between inhibitor and protein were applied as described in footnote 11. If the conformation of the modeled structure displayed unfavorable interactions or did not fulfill the distance constrain requirements to a large extent, the starting conformation was manually modified and the new conformer was subjected again to minimization procedures A and B.
20. The phenolic O-alkylation was done in analogy to: Chung, J. Y. L.; Zhao, D.; Hughes, D. L.; Grabowski, E. J. J. A Practical Synthesis of Fibrinogen Receptor Antagonist MK-383. Selective Functionalisation of (S)-Tyrosine. Tetrahedron 1993, 49, 5767-5776.
21. Ghosh, A. K.; Thompson, W. J.; McKee, S. P.; Duong, T. T.; Lyle, T. A.; Chen, J. C.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Huff, J. R.; Anderson P. S. 3-Tetrahydrofuran and Pyran Urethanes as High-Affinity P2-Ligands for HIV-1 Protease Inhibitors. J. Med. Chem. 1993, 36, 292-294.
22. Vella, S. Update on a Proteinase Inhibitor. AIDS 1994, 8 (suppl 3), S25-S29.
23. Kobler, A.; Malter, M. Quinoline Carboxylic Acid Amides. CIBA U.S.P: 2798873 (1953).
24. Billich, A.; Hammerschmid, F.; Winkler, G. Purification, Assay and Kinetic Features of HIV-1 proteinase. Biol. Chem. Hoppe-Seyler 1990, 371, 265-272.
25. Richards, A.; Phylip, L. H.; Farmerie, W. G.; Scarborough, P. E.; Alvarez, A.; Dunn, B. M.; Hirel, P. H.; Konvalinka, J.; Strop, P.; Pavlickova, L.; Kostka, V.; Kay, J. Sensitive, Soluble Chromogenic Substrates for HIV-1 Proteinase. J. Biol. Chem. 1990, 265, 7733-7736.
26. Rosenwirth, B.; Billich, A.; Datema, R.; Donatsch, P.; Hammerschmid, F.; Harrison, R.; Hiestand, P.; Jaksche, H.; Mayer, P.; Peichl, P.; Quesniaux, V.; Schatz, F.; Schuurman, H. H.; Traber, R.; Wenger, R.; Wolff, B.; Zenke, G.; Zurini, M. Inhibition of HIV-1 Replication by SDZ NIM 811, a Non-Immunosuppressive Cyclosporin A Analog. Antimicrob. Agents Chemother. 1994, 38, 1763-1772.
27. Gartner, S.; Markovits, P.; Markovits, D. M.; Kaplan, M. H.; Gallo, R. C.; Popovic, M. The Role of Mononuclear Phagocytes in HTLV-III/LAV Infection. Science 1988, 233, 215-219.
28. Rey, M. A.; Krust, B.; Laurent, A. G.; Guetard, D.; Montagnier, L.; Hovanessian, A. G. Characterization of an HIV-2 Related Virus with a Smaller Sized Extracellular Envelope Glycoprotein. Virology 1989, 173, 258-267.
29. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; De Clerq, E. Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of anti-HIV Compounds. J. Virol. Methods 1988, 20, 309-321.
30. Perno, C. F.; Yarchoan, R.; Cooney, D. A.; Hartman, N. R.; Webb, D. S. A.; Hao, Z.; Mitsuya, H.; Johns, D. G.; Broder, S. Replication of Human Immuno-Deficiency Virus in Monocytes. J. Exp. Med. 1989, 169, 933-951.
31. DeClerq, E.; Yamamoto, N.; Pauwels, R.; Balzarini, J.; Witvrouw, M.; De Vreese, K.; Debyser, Z.; Rosenwirth, B.; Peichl, P.; Datema, R.; Thornton, D.; Skerlj, R.; Gaul, F.; Padmanabhan, S.; Bridger, G.; Henson, G.; Abrams, M. Highly Potent and Selective Inhibition of Human Immunodeficiency Virus by the Bicylam Derivative JM3100. Antimicrob. Agents Chemother. 1994, 38, 668-674.